Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry.

IF 2.6 3区医学 Q2 OPHTHALMOLOGY

Journal of cataract and refractive surgery Pub Date : 2024-10-11 DOI:10.1097/j.jcrs.0000000000001567

Colin I Clement, Vuong Nguyen, Frank Howes, Jenny Danks, Vincent Lee, David Wechsler, Emily Gregory Roberts, Mark Gillies, Mitchell Lawlor

{"title":"Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry.","authors":"Colin I Clement, Vuong Nguyen, Frank Howes, Jenny Danks, Vincent Lee, David Wechsler, Emily Gregory Roberts, Mark Gillies, Mitchell Lawlor","doi":"10.1097/j.jcrs.0000000000001567","DOIUrl":null,"url":null,"abstract":"Purpose: To compare combined phacoemulsification and iStent inject to phacoemulsification alone.Setting: Fight Glaucoma Blindness (FGB) registry - Australia.Design: Prospective observational registry study.Methods: Eyes that had combined phacoemulsification with iStent inject (iStent group) were compared to eyes that had phacoemulsification only (cataract alone). Primary outcome was percentage of eyes achieving >20% IOP reduction from baseline 12 months after surgery. Secondary outcomes included mean IOP and medication reduction, adverse events and secondary procedures.Results: At 12 months the percentage of eyes achieving >20% reduction of IOP at 12 months was significantly higher in the iStent group compared to the cataract alone group (40.9% vs 30.1% p<0.001). Adverse events occurred at a low rate in both groups, and secondary IOP lowering procedures were significantly less frequent in the iStent group compared to cataract alone.Conclusions: Real-world outcomes from the FGB registry at 12 months show phacoemulsification combined with iStent inject has higher efficacy and a reduced need for secondary IOP lowering surgery compared to phacoemulsification alone.","PeriodicalId":15214,"journal":{"name":"Journal of cataract and refractive surgery","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cataract and refractive surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/j.jcrs.0000000000001567","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare combined phacoemulsification and iStent inject to phacoemulsification alone.

Setting: Fight Glaucoma Blindness (FGB) registry - Australia.

Design: Prospective observational registry study.

Methods: Eyes that had combined phacoemulsification with iStent inject (iStent group) were compared to eyes that had phacoemulsification only (cataract alone). Primary outcome was percentage of eyes achieving >20% IOP reduction from baseline 12 months after surgery. Secondary outcomes included mean IOP and medication reduction, adverse events and secondary procedures.

Results: At 12 months the percentage of eyes achieving >20% reduction of IOP at 12 months was significantly higher in the iStent group compared to the cataract alone group (40.9% vs 30.1% p<0.001). Adverse events occurred at a low rate in both groups, and secondary IOP lowering procedures were significantly less frequent in the iStent group compared to cataract alone.

Conclusions: Real-world outcomes from the FGB registry at 12 months show phacoemulsification combined with iStent inject has higher efficacy and a reduced need for secondary IOP lowering surgery compared to phacoemulsification alone.

查看原文本刊更多论文

iStent 注射与白内障手术的纵向疗效对比：来自抗击青光眼致盲登记处的真实世界数据。

目的：比较联合超声乳化和注射 iStent 与单纯超声乳化：澳大利亚抗击青光眼致盲（FGB）登记处：前瞻性观察登记研究：将接受联合超声乳化术和 iStent 注入术的眼睛（iStent 组）与只接受超声乳化术的眼睛（单纯白内障组）进行比较。主要结果是术后 12 个月眼压较基线降低 20% 以上的眼球百分比。次要结果包括平均眼压和药物减量、不良事件和二次手术：结果：与单纯白内障组相比，iStent 组 12 个月后眼压降低 >20% 的比例明显更高（40.9% 对 30.1%）：FGB 登记 12 个月的实际结果显示，与单纯超声乳化术相比，超声乳化术联合注射 iStent 的疗效更高，二次降低眼压手术的需求也更少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

$Journal of cataract and refractive surgery$

Journal of cataract and refractive surgery 医学-外科

CiteScore

5.60

自引率

14.30%

发文量

259

审稿时长

8.5 weeks

期刊介绍： The Journal of Cataract & Refractive Surgery (JCRS), a preeminent peer-reviewed monthly ophthalmology publication, is the official journal of the American Society of Cataract and Refractive Surgery (ASCRS) and the European Society of Cataract and Refractive Surgeons (ESCRS). JCRS publishes high quality articles on all aspects of anterior segment surgery. In addition to original clinical studies, the journal features a consultation section, practical techniques, important cases, and reviews as well as basic science articles.